Compounds > 1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione
Page last updated: 2024-11-08
1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione
Description
1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione: hypoglycemic agent; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 197004 |
SCHEMBL ID | 23295123 |
MeSH ID | M0050837 |
Synonyms (11)
Synonym |
brn 0733524 |
1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione |
butaglionamide |
benzenesulfonamide, 4,4'-(4-butyl-3,5-dioxo-1,2-pyrazolidinediyl)bis- |
4,4'-(4-butyl-3,5-dioxo-1,2-pyrazolidinediyl)bisbenzenesulfonamide |
butaglyonamide |
4-[4-butyl-3,5-dioxo-2-(4-sulfamoylphenyl)pyrazolidin-1-yl]benzenesulfonamide |
5-24-05-00408 (beilstein handbook reference) |
2603-23-8 |
DTXSID60180675 |
SCHEMBL23295123 |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 13.13 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.92 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |